Track topics on Twitter Track topics that are important to you
Appendiceal epithelial neoplasms are rare cancers. Management of peritoneal disease from appendiceal neoplasms has historically been with debulking surgery. In recent decades, the advent of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care. Here, we report our single institution 10-year experience with CRS and HIPEC for appendiceal neoplasms.
This article was published in the following journal.
Name: ANZ journal of surgery
Complete cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been proven to lengthen survival in appendiceal peritoneal carcinomatosis (PC-A). The aim of thi...
As the management of metastatic colorectal cancer (CRC) has evolved over the past decades, optimal management of CRC with peritoneal metastases remains controversial, especially about cytoreductive su...
The aim of the present study is to evaluate and validate the PSDSS score as a prognostic tool in patients with stage IIIC-IV epithelial ovarian cancer (EOC) who are treated with a first cytoreduction ...
Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) is used in specialised units outside of gynaecological cancer centres in Australia and New Zealand to treat advanced epithelial ovar...
Recent advances, specifically cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), offer advantages compared to the traditional therapeutic approach of systemic chemotherap...
The goal of this clinical research study is to learn whether cytoreduction surgery (surgery to reduce or remove lesions), gastrectomy (where all or part of the stomach is removed), and hyp...
The current standard treatment for ovarian cancer, tubal cancer, and primary peritoneal cancer is maximal cytoreductive surgery followed by chemotherapy. Recent randomized trials of Gyneco...
This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemo...
This is a phase II open label, single arm clinical trial on safety and efficacy exploring an short-course regimen of intra-operative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as up...
Gastric cancer associated peritoneal carcinomatosis has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to...
Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Tumors or cancer of the APPENDIX.
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...